Overview

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Status:
Not yet recruiting
Trial end date:
2026-07-27
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Bemarituzumab